Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR4640 (ruzinurad) multiple dose study in healthy subjects
NCT02890966Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jul 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ruzinurad in gout and hyperuricemia (4 cohorts), sponsored by Hengrui. Primary endpoint: Adverse events. Started Jul 2016; status: completed.
02
Drugs
ruzinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT02890966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02890966.